Predicted protein targets (top 7)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | FFAR1 | O14842 | 12/20 | 0.61 |
| ▸ | KEAP1 | Q14145 | 1/20 | 0.59 |
| ▸ | FFAR4 | Q5NUL3 | 3/20 | 0.52 |
| ▸ | CA1 | P00915 | 1/20 | 0.52 |
| ▸ | CA2 | P00918 | 1/20 | 0.52 |
| ▸ | TBXAS1 | P24557 | 3/20 | 0.49 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.48 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL3962759 | 0.89 | FFAR1 (0.70) | FFAR1KEAP1FFAR4 | |
| SCHEMBL6001141 | 0.88 | SMN1; SMN2 (0.62) | FFAR1KEAP1TBXAS1ALDH1A1 | |
| SCHEMBL23174459 | 0.86 | MAPT (0.61) | FFAR1TBXAS1 | |
| SCHEMBL18269510 | 0.85 | FFAR1 (0.72) | FFAR1FFAR4 | |
| SCHEMBL28849639 | 0.85 | FFAR1 (0.57) | FFAR1KEAP1FFAR4 | |
| SCHEMBL10897221 | 0.85 | MAPT (0.65) | FFAR1TBXAS1 | |
| SCHEMBL69746 | 0.84 | FFAR1 (0.81) | FFAR1KEAP1FFAR4CA1CA2 | |
| SCHEMBL8489989 | 0.82 | HCAR2 (0.59) | FFAR1KEAP1FFAR4 | |
| Hydrochloric Acid SCHEMBL25264643 | 0.82 | FFAR1 (0.77) | FFAR1KEAP1FFAR4CA1CA2 | |
| SCHEMBL24167624 | 0.82 | ALDH1A1 (0.59) | FFAR1ALDH1A1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 132 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20080194659-A1 | Cinnamic, Phenylpropiolic and Phenylpropanoic Acid Derivatives Useful as Anti-Tumor Agents | SIGMA-TAU FARMACEUTICHE RIUNITE S.P.A. (IT) | 2008-08-14 | — | — | US | claimed |
| EP-1893561-A1 | CINNAMIC, PHENYLPROPIOLIC AND PHENYLPROPANOIC ACID DERIVATIVES USEFUL AS ANTI-TUMOUR AGENTS | SIGMA-TAU Industrie Farmaceutiche Riunite S.p.A. (IT) | 2008-03-05 | — | — | EP | claimed |
| WO-2006131482-A1 | CINNAMIC, PHENYLPROPIOLIC AND PHENYLPROPANOIC ACID DERIVATIVES USEFUL AS ANTI-TUMOUR AGENTS | SIGMA-TAU INDUSTRIE FARMACEUTICHE RIUNITE S.P.A. (IT) | 2006-12-14 | — | — | WO | claimed |
| CN-1580108-A | Phosphorus-containing compound | ARTIFICIAL RESIN FACTORY CO LT (CN) | 2005-02-16 | — | — | CN | claimed |
| EP-4746874-A2 | SMALL MOLECULE PROTEIN DEGRADERS OF KRAS G12D MUTANT | Merck Sharp & Dohme LLC (US) | 2026-05-27 | — | — | EP | disclosed |
| EP-4747239-A1 | SMALL MOLECULE PROTEIN DEGRADERS OF KRAS G12D MUTANT | Merck Sharp & Dohme LLC (US) | 2026-05-27 | — | — | EP | disclosed |
| US-20250325542-A1 | INHIBITORS OF ANTIMOCROBIAL RESISTANCE AND METHOS USING SAME | BAYLOR COLLEGE MEDICINE (US) | 2025-10-23 | — | — | US | disclosed |
| WO-2025019823-A1 | SMALL MOLECULE PROTEIN DEGRADERS OF KRAS G12D MUTANT | MERCK SHARP & DOHME LLC (US) | 2025-01-23 | — | — | WO | disclosed |
| WO-2025019819-A2 | SMALL MOLECULE PROTEIN DEGRADERS OF KRAS G12D MUTANT | MERCK SHARP & DOHME LLC (US) | 2025-01-23 | — | — | WO | disclosed |
| WO-2023250467-A2 | INHIBITORS OF ANTIMICROBIAL RESISTANCE AND METHODS USING SAME | BAYLOR COLLEGE OF MEDICINE (US) | 2023-12-28 | — | — | WO | disclosed |
| US-20220340893-A1 | BI-FUNCTIONAL COMPLEXES AND METHODS FOR MAKING AND USING SUCH COMPLEXES | NUEVOLUTION A/S (DK) | 2022-10-27 | — | — | US | disclosed |
| US-20220259490-A1 | LIGAND-EXCHANGEABLE JANUS NANOPARTICLES AND METHODS OF MAKING THE SAME | Alliance for Energy Innovation, LLC | 2022-08-18 | — | — | US | disclosed |
| WO-1996023813-A1 | PEPTIDES AND COMPOUNDS THAT BIND TO SH2 DOMAINS | AFFYMAX TECHNOLOGIES N.V. (AN) | 1996-08-08 | — | — | WO | disclosed |
| EP-0689845-A2 | Conjugates of methyltrithio antitumor agents and intermediates for their synthesis | AMERICAN CYANAMID COMPANY (US) | 1996-01-03 | — | — | EP | disclosed |
| EP-0330241-A2 | Calcitonin derivatives | OTSUKA PHARMACEUTICAL CO., LTD. (JP) | 1989-08-30 | — | — | EP | disclosed |
| US-4238589-A | A 1-TERT-AMINO-4-PHENYL-2-(CARBOXY-SUBSTITUTED PHENYL)-1-BUTEN-3,4-DIONE; CHEMICAL INTERMEDIATE | HOFFMANN-LA ROCHE INC. (US) | 1980-12-09 | — | — | US | disclosed |
| US-4045487-A | FLUOROGENIC REAGENTS | HOFFMANN-LA ROCHE INC. (US) | 1977-08-30 | — | — | US | disclosed |
| US-4038289-A | FLUORESCENT LABELING, BIOLOGICAL | HOFFMANN-LA ROCHE INC. (US) | 1977-07-26 | — | — | US | disclosed |
| US-4018884-A | Fluorogenic materials and labeling techniques | HOFFMANN-LA ROCHE INC. (US) | 1977-04-19 | — | — | US | disclosed |
| US-3969373-A | Fluorogenic 2-oxy-3(2H)-furanone materials | HOFFMANN-LA ROCHE INC. (US) | 1976-07-13 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20080194659-A1 | Cinnamic, Phenylpropiolic and Phenylpropanoic Acid Derivatives Useful as Anti-Tumor Agents | ABCC1, VHL, ABCB1 | FFAR1 401/4885KEAP1 323/4885FFAR4 899/4885 |
| US-20250325542-A1 | INHIBITORS OF ANTIMOCROBIAL RESISTANCE AND METHOS USING SAME | BPGM, PNMT, DDT | FFAR1 4487/4885KEAP1 200/4885FFAR4 4803/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.